Femotol30 mg

Femotol 30 mg is indicated for the treatment of iron deficiency and iron deficiency anemia (IDA) in adults.

It is commonly used for:

• Iron deficiency anemia (IDA) due to chronic blood loss, poor absorption, or nutritional deficiency
• Iron deficiency without anemia where iron stores are depleted
• Patients intolerant to conventional oral iron therapy due to gastrointestinal side effects
• Chronic conditions associated with iron loss or malabsorption (e.g., inflammatory bowel disease)

Femotol 30 mg helps restore iron levels and improve hemoglobin production while offering better gastrointestinal tolerability compared to traditional iron salts.

Femotol 30 mg is an oral iron complex that delivers ferric iron in a stable form for efficient absorption through the intestinal mucosa. Once absorbed, iron is released and transported in the bloodstream by transferrin, where it is utilized for hemoglobin synthesis or stored as ferritin.

Femotol 30 mg helps restore depleted iron stores by increasing key iron parameters, including serum ferritin and transferrin saturation (TSAT). This leads to improved iron availability for red blood cell production and correction of iron deficiency.

Unlike traditional iron salts, Femotol 30 mg is designed to enhance iron absorption while improving gastrointestinal tolerability, making it suitable for patients who cannot tolerate conventional oral iron therapy.

Femotol 30 mg may interact with certain medications and food, potentially affecting absorption and therapeutic effectiveness.

With medicines:

• Dimercaprol: Concomitant use may increase the risk of nephrotoxicity; therefore, this combination should be avoided.
• Mycophenolate, Ciprofloxacin, Doxycycline, Ethinyl estradiol: Femotol 30 mg may reduce the absorption and bioavailability of these drugs, potentially decreasing their effectiveness.
• General oral medicines: If clinically significant interactions are expected, it is recommended to separate administration by at least 4 hours.

With food:

• Food may reduce the absorption of iron, leading to decreased bioavailability and reduced therapeutic effect. It is generally recommended to take Femotol 30 mg on an empty stomach for optimal absorption.

Femotol 30 mg is generally well tolerated, but some patients may experience gastrointestinal side effects during treatment.

Common side effects include:

• Gastrointestinal symptoms: Nausea, vomiting, abdominal pain, diarrhea, or constipation
• Flatulence (gas formation)
• Discolored stools (dark or black stools)

These side effects are usually mild, temporary, and tend to improve with continued use as the body adjusts to iron therapy.

If symptoms persist or become severe, medical advice should be sought for proper evaluation and dose adjustment.

Femotol 30 mg has minimal systemic absorption as an intact complex after oral administration, which limits direct fetal or infant exposure.

Pregnancy:
Due to its minimal systemic absorption, maternal use of Femotol 30 mg is not expected to result in significant fetal exposure. It may be used during pregnancy when iron supplementation is clinically indicated, under medical supervision.

Lactation (Breastfeeding):
There are no specific data on the presence of Femotol 30 mg in human breast milk or its effects on the breastfed infant. However, systemic exposure to the intact drug in the mother is minimal, and exposure to the infant through breastfeeding is not expected to be significant.

General advice:
Femotol 30 mg should be used during pregnancy and lactation only when iron therapy is necessary, under appropriate medical guidance.

Femotol 30 mg should be used with caution to ensure safe and effective iron supplementation, especially in patients with underlying gastrointestinal or iron metabolism disorders.

Key precautions include:

• Active inflammatory bowel disease (IBD): Avoid use during active IBD flare-ups, as it may potentially worsen gastrointestinal inflammation.
• Iron overload conditions: Do not use in patients with iron overload disorders or those already receiving intravenous iron therapy.
• Monitoring requirements: Iron parameters (such as serum ferritin and transferrin saturation) should be assessed before starting therapy and monitored regularly during treatment.
• Pediatric safety warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years; strict storage and supervision are essential.
• Overdose risk: In case of suspected iron overdose, immediate medical attention is required.

General warning:
Femotol 30 mg should only be used under medical supervision with appropriate monitoring to avoid iron overload and ensure safe treatment outcomes.

Femotol 30 mg overdose data in humans is limited; however, excessive iron intake may lead to clinically significant toxicity.

Early signs and symptoms of overdose may include:

• Nausea and vomiting
• Abdominal pain
• Diarrhea

Severe overdose effects may include:

• Reduced tissue perfusion (hypoperfusion)
• Metabolic acidosis
• Systemic iron toxicity

Long-term consequences of chronic overdose:

• Excess iron accumulation in body tissues
• Development of hemosiderosis (iron deposition in organs)

General advice:
In case of suspected overdose, immediate medical attention is required. Careful dosing and regular monitoring of iron levels are essential to prevent iron accumulation and toxicity.

Store in a cool (below 25°C) and dry place protected from light. Keep away from the reach of children.